Cargando…
Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
Nitrogen-containing bisphosphonates are potent inhibitors of osteoclastic bone resorption. With their individually proven efficacy to significantly reduce the incidence of vertebral and/or non-vertebral fractures and with their overall beneficial safety profile, alendronate, ibandronate, risedronate...
Autores principales: | Bock, Oliver, Felsenberg, Dieter |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546473/ https://www.ncbi.nlm.nih.gov/pubmed/18686751 |
Ejemplares similares
-
Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
por: Sunyecz, John
Publicado: (2008) -
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006) -
Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010) -
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010) -
Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis
por: Rizzoli, René, et al.
Publicado: (2011)